• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ethical Considerations in Microbial Therapeutic Clinical Trials.微生物治疗临床试验中的伦理考量
New Bioeth. 2017 Nov;23(3):210-218. doi: 10.1080/20502877.2017.1387386. Epub 2017 Oct 17.
2
Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.基于粪便微生物群的治疗方法用于复发性艰难梭菌感染、溃疡性结肠炎和肥胖症。
EBioMedicine. 2016 Nov;13:37-45. doi: 10.1016/j.ebiom.2016.09.029. Epub 2016 Oct 1.
3
Is fecal microbiota transplantation a temporary patch for treatment of Clostridium difficile infection or a new frontier of therapeutics?粪便微生物群移植是艰难梭菌感染治疗的临时补救措施还是治疗学的新前沿？
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):435-438. doi: 10.1080/17474124.2018.1465818. Epub 2018 Apr 20.
4
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.
5
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.造血干细胞移植受者复发性艰难梭菌感染的粪便微生物群移植
Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.
6
Fecal microbiota transplantation for Clostridium difficile infection: back to the future.粪菌移植治疗艰难梭菌感染：回归未来。
Expert Opin Biol Ther. 2015 Jul;15(7):1001-14. doi: 10.1517/14712598.2015.1045872.
7
Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation.预测包裹粪菌移植后艰难梭菌感染的复发。
Microbiome. 2018 Sep 18;6(1):166. doi: 10.1186/s40168-018-0549-6.
8
Fecal microbiota transplantation for the treatment of Clostridium difficile infection.粪便微生物群移植治疗艰难梭菌感染
J Hosp Med. 2016 Jan;11(1):56-61. doi: 10.1002/jhm.2449. Epub 2015 Sep 7.
9
Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.用于复发性艰难梭菌感染的粪便微生物群移植供体及粪便样本的实验室检测
J Clin Microbiol. 2017 Apr;55(4):1002-1010. doi: 10.1128/JCM.02327-16. Epub 2017 Jan 11.
10
Development of fecal microbiota transplantation suitable for mainstream medicine.开发适合主流医学的粪便微生物移植。
Clin Gastroenterol Hepatol. 2015 Feb;13(2):246-50. doi: 10.1016/j.cgh.2014.11.014. Epub 2014 Nov 20.

引用本文的文献

1
Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.癌症治疗中的前沿融合：纳米材料、间充质干细胞和微生物制剂的作用——挑战与局限
Discov Oncol. 2024 Dec 21;15(1):818. doi: 10.1007/s12672-024-01590-0.
2
Microbial Therapy and Breast Cancer Management: Exploring Mechanisms, Clinical Efficacy, and Integration within the One Health Approach.微生物治疗与乳腺癌管理：探究机制、临床疗效及在大健康方法中的整合。
Int J Mol Sci. 2024 Jan 16;25(2):1110. doi: 10.3390/ijms25021110.
3
Introducing the microbiome: Interdisciplinary perspectives.微生物组介绍：跨学科视角。
Endeavour. 2022 Mar-Jun;46(1-2):100817. doi: 10.1016/j.endeavour.2022.100817. Epub 2022 Jun 3.
4
Medical students' perception on fecal microbiota transplantation.医学生对粪便微生物群移植的看法。
BMC Med Educ. 2019 Oct 11;19(1):368. doi: 10.1186/s12909-019-1804-7.

本文引用的文献

1
The AGA's Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics.美国胃肠病学会的粪便微生物群移植国家登记处：迈向了解微生物群疗法风险与益处的重要一步。
Gastroenterology. 2017 Mar;152(4):681-684. doi: 10.1053/j.gastro.2017.01.028. Epub 2017 Jan 29.
2
Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review.粪便微生物群移植中粪便供体选择与筛查的挑战：综述
Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27.
3
Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella pneumoniae - Washoe County, Nevada, 2016.实地记录：产泛耐药新德里金属β-内酰胺酶的肺炎克雷伯菌——内华达州瓦肖县，2016年
MMWR Morb Mortal Wkly Rep. 2017 Jan 13;66(1):33. doi: 10.15585/mmwr.mm6601a7.
4
Navigating social and ethical challenges of biobanking for human microbiome research.应对人类微生物组研究生物样本库的社会和伦理挑战。
BMC Med Ethics. 2017 Jan 11;18(1):1. doi: 10.1186/s12910-016-0160-y.
5
Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection.粪便过滤移植治疗艰难梭菌感染的疗效。
Gastroenterology. 2017 Mar;152(4):799-811.e7. doi: 10.1053/j.gastro.2016.11.010. Epub 2016 Nov 17.
6
Ensuring the safe and effective FDA regulation of fecal microbiota transplantation.确保美国食品药品监督管理局对粪便微生物群移植进行安全有效的监管。
J Law Biosci. 2015 Jul 6;2(2):396-415. doi: 10.1093/jlb/lsv032. eCollection 2015 Jul.
7
Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.粪便微生物群移植对多次复发性艰难梭菌感染复发的影响：一项随机试验
Ann Intern Med. 2016 Nov 1;165(9):609-616. doi: 10.7326/M16-0271. Epub 2016 Aug 23.
8
Systematic Review: Adverse Events of Fecal Microbiota Transplantation.系统评价：粪便微生物群移植的不良事件
PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016.
9
Addressing Benefits, Risks and Consent in Next Generation Sequencing Studies.下一代测序研究中的益处、风险与知情同意
J Clin Res Bioeth. 2015 Dec;6(6). doi: 10.4172/2155-9627.1000249. Epub 2015 Dec 14.
10
The National Institutes of Health Human Microbiome Project.美国国立卫生研究院人类微生物组计划
Semin Fetal Neonatal Med. 2016 Dec;21(6):368-372. doi: 10.1016/j.siny.2016.05.002. Epub 2016 Jun 29.

微生物治疗临床试验中的伦理考量

Ethical Considerations in Microbial Therapeutic Clinical Trials.

作者信息

Woodworth Michael H, Sitchenko Kaitlin L, Carpentieri Cynthia, Friedman-Moraco Rachel J, Wang Tiffany, Kraft Colleen S

机构信息

a Department of Medicine, Division of Infectious Diseases , Emory University School of Medicine , Atlanta , GA , USA.

b Emory University School of Medicine , Atlanta , GA , USA.

出版信息

New Bioeth. 2017 Nov;23(3):210-218. doi: 10.1080/20502877.2017.1387386. Epub 2017 Oct 17.

DOI:10.1080/20502877.2017.1387386
PMID:29039256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5996990/
Abstract

As understanding of the human microbiome improves, novel therapeutic targets to improve human health with microbial therapeutics will continue to expand. We outline key considerations of balancing risks and benefits, optimising access, returning key results to research participants, and potential conflicts of interest.

摘要

随着对人类微生物组的认识不断提高，利用微生物疗法改善人类健康的新治疗靶点将持续增加。我们概述了平衡风险与益处、优化获取途径、向研究参与者反馈关键结果以及潜在利益冲突等关键考量因素。